NMC Healthcare is UAE’s largest private healthcare provider. It has two main branches of business, NMC Healthcare and NMC Trading.
From a one room clinic in Abu Dhabi to a global healthcare enterprise in 40 years – this is the journey called NMC.
Since its inception, NMC has been chalking out distinct growth strategies that reflect the continuing leadership in the market. Having focused on expanding the capacities and building new capabilities, NMC has developed specialised verticals covering multi-specialty care, maternity and fertility, long-term and home care, operations and management and distribution services.
Over the years, NMC has earned the trust of millions, thanks to its personalised care and a sincere commitment to the overall well-being of the community it serves.
With a team of over 2,000 doctors and 18,000 paramedical and support personnel, NMC owns and manages over 135 healthcare facilities that includes hospitals, medical centres, long term care facilities, day surgery centres, fertility centres and home health services providers.
Every year, over 8.5 million patients are treated by NMC doctors across UAE, Saudi Arabia, Kuwait, Oman, UK, Spain, Italy, Denmark, Slovakia, Egypt, Brazil and Colombia.
NMC was the first company from Abu Dhabi to list on the London Stock Exchange and is now part of the FTSE 100 Index, an elite club of top 100 blue-chip companies by market cap.

30 Apr Investec 900.00 Buy

5 May Jefferies... 1,000.00 Buy

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 869.50. Over this period, the share price is up 86.59%.

Acquisition of Pro Vita

Statement re Possible Offer
RNS
RNS Number : 8442B
Al Noor Hospitals Group PLC
09 October 2015



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION



THIS ANNOUNCEMENT IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER WILL BE MADE



FOR IMMEDIATE RELEASE

October 9th, 2015



The Board of Al Noor Hospitals Group Plc (the "Company") notes the recent media speculation in relation to the Company and confirms that it has received an approach from NMC Health Plc ("NMC") regarding a possible offer.



In accordance with Rule 2.6(a) of the Code, NMC is required, by not later than 5.00 p.m. on November 6th, 2015, to either announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Panel in accordance with Rule 2.6(c) of the Code.

NMC Health remains committed to a combination
StockMarketWire.com
NMC Health notes the announcement today by Al Noor Hospital Group and Mediclinic International Ltd.

"This confirms our belief in the competitiveness of our initial possible offer and that the combination of NMC and Al Noor has the strongest strategic and financial rationale for all stakeholders," it said in a statement.

"We reiterate our commitment to this opportunity despite the lack of meaningful engagement from the Board of Al Noor.

"We plan to issue a further announcement in due course. We would urge shareholders to take no action at this time."



At 9:22am:
(LON:ANH) Al Noor Hospitals Group PLC share price was +134p at 1128.5p
(LON:NMC) NMC Health PLC share price was +20p at 828.5p


Story provided by StockMarketWire.com

Company News

NMC Health abandons bid for Al Noor Hospitals

Mon, 16 November 2015




(ShareCast News) - NMC Health has abandoned its bid for Al Noor Hospitals, meaning South Africa's Mediclinic International looks set to clinch a deal with the Abu Dhabi-based healthcare operator.
Al Noor confirmed in early October that it had received an approach from NMC regarding a possible offer.

NMC said on Monday: "After a thorough assessment of the opportunity, NMC has concluded that the potential transaction would not deliver sufficient returns or shareholder value in line with its stated policy, and accordingly NMC now confirms that it does not intend to make an offer for Al Noor."

Last month, the boards of Al Noor and Mediclinic reached an agreement on the terms of a possible merger.

Under the proposed deal announced, Al Noor will acquire Mediclinic, with shareholders receiving 0.625 new shares for each Mediclinic share held.

The proposed deal will result in Mediclinic shareholders owning 84% to 93% of the enlarged group.

The groups said the merger will create a "leading international private healthcare group with deep operational expertise and a well-balanced geographic profile in Southern Africa, Switzerland and the United Arab Emirates".

At 1450 GMT, NMC Health shares were up 1.9% to 773.50p, while Al Noor was flat at 1,158p

Company News

NMC Health focuses on organic expansion after ditching Al Noor bid

Thu, 19 November 2015


NMC Health focuses on organic expansion after ditching Al Noor bid
(ShareCast News) - Emirates-based healthcare provider NMC Health reiterated its commitment to expanding capacity in the UAE and elsewhere, having announced earlier in the week that it had abandoned its bid for Al Noor Hospitals.
NMC said on Monday that after a thorough assessment of the opportunity, it had concluded that the potential transaction with Al Noor "would not deliver sufficient returns or shareholder value in line with its stated policy".

On Thursday, it looked as though the company was putting all that behind it.

The group said it has reviewed and assessed multiple proposed inorganic, organic and partnership opportunities over the past year and continues to be highly selective and disciplined in its investment process.

Deputy chief executive Prasanth Manghat said: "Over the past year we continued to execute our updated strategy in a highly dedicated and methodical manner with full focus on meeting our strategic objectives and delivering sustainable long-term growth, strategic and competitive advantages and shareholder returns.

"We look to the future and continue to see very favourable healthcare market dynamics and substantial growth opportunities for NMC Health in the UAE and the wider region."

NMC said it has completed four strategic and value-accretive acquisitions in the year to date, including fertility treatment company Clinica Eugin, ventilated care provider ProVita, homecare services provider Americare and UAE-based primary care provider Dr. Sunny Network.

The company expects to have 885 licensed beds available by the end of this year and a network of medical centres and day surgeries.

At 1430 GMT, NMC shares were down 0.4% at 764p.

Acquisition
RNS
RNS Number : 7427G
NMC Health Plc
24 November 2015



24 November 2015 - NMC Health plc expands its Maternity & Fertility vertical through the acquisition of a majority stake in Fakih IVF

NMC Health plc (LSE:NMC) ('NMC' or the 'Company'), the leading integrated healthcare provider operating across the United Arab Emirates, is pleased to announce that it has entered into an agreement to acquire a 51% shareholding in Fakih IVF Group ('Fakih IVF') for AED696m (US$189 m). NMC has also agreed a mechanism by which it could increase its stake in Fakih IVF over time, based on certain conditions being met. Based on unaudited management accounts, Fakih IVF generated an EBITDA of US$25m for the nine months ended 30 September 2015, an increase of 20% year-on-year (YoY).

Fakih IVF, which comprises of Fakih IVF LLC and Fakih IVF Fertility Center LLC, is the Middle East market leader for in-vitro fertilisation (IVF) services, performing over 4,000 IVF cycles per annum and offering the only full service genetics laboratory in the region. Fakih IVF currently operates centres in both Abu Dhabi and Dubai and is looking to expand its footprint within the UAE as well as in the Gulf Cooperation Council (GCC) region. Fakih IVF is expected to open three additional UAE centres during 2016 in Al Ain city, Western region of Abu Dhabi Emirate and Sharjah. Fakih IVF has also achieved considerable progress in its regional expansion plan with IVF centres expected in both Qatar and Oman before year end 2016.

The transaction is aligned with NMC's Group strategy of establishing the company as a top in-class integrated provider of specialist care across its existing multi-brand and multi-segment healthcare verticals. This acquisition confirms the NMC Maternity & Fertility vertical's global market position, as one of the leading international providers of fertility treatment services based on;

§ Scale of its global business and cycle capacity

§ Focused strategic initiative towards raising capabilities and access to care in high growth and under-supplied markets

§ Segment leading treatment capabilities and success rates

§ Diversity and complexity of service offering across the fertility treatment spectrum

§ Established presence and referral centres across regulatory geographies to facilitate one-stop approach for patients

NMC Maternity & Fertility vertical now includes:

§ Brightpoint Royal Women's Hospital - Most advanced women's and maternity care hospital in the Middle East

§ Clinica Eugin - Top global fertility care provider based in Europe

§ Fakih IVF (51%) - UAE based Middle Eastern leader with the only full service genetics laboratory in the region

The combination with Fakih IVF is expected to be highly synergistic with significant potential for cross-referral of patients and transfer of best practices and technologies within NMC's Maternity & Fertility vertical. Patients will have access to an integrated continuum of care with complementing capabilities and coordinated seamless service offering including local IVF treatments of the highest international standards at Fakih IVF, international referral to Clinica Eugin and its wider fertility service offering as permitted by its operational and regulatory environment and NMC's hospitals, led by Brightpoint, for antenatal, delivery and postnatal services.

Furthermore, this transaction will increase the company's penetration into the Thiqa insurance segment, which is exclusively comprised of UAE nationals in Abu Dhabi, where fertility treatment is covered.

In addition, fertility treatments are one of the leading drivers of medical tourism in the UAE and the acquisition of Fakih IVF will position NMC as the destination of choice for fertility treatments with a complete service offering delivered by Fakih IVF and Clinica Eugin.

Over 50% of patients treated by Fakih IVF in Dubai are expatriates with over 25% being medical tourists. Approximately 80% of patients treated by Fakih IVF in Abu Dhabi are Emirati nationals covered by Thiqa insurance.

Dr. Michael Fakih, the founder and 100% beneficial owner of Fakih IVF, will remain as a 49% shareholder and Managing Partner in the business, thereby ensuring a smooth transition and limiting any potential integration risk. Dr. Fakih is also a renowned research professional with over a hundred international publications. He has been instrumental in his professional career for over 20,000 births from infertile couples using only IVF.

Dr. B.R. Shetty, Chief Executive Officer at NMC Health, commented:

"Our acquisition of a major shareholding in Fakih IVF is the logical next step towards achieving NMC's goal of becoming a global leader in maternity and fertility services. We are particularly excited about growing our in vitro fertilisation service offering within the UAE and look forward to further expand its geographic reach."

Information on Fakih IVF

Fakih IVF Group was founded in Dubai in 2011 by Dr. Michael Fakih, who has been established as a leading IVF physician in the USA and the UAE for over 20 years. The business expanded into Abu Dhabi in 2013 and currently performs over 4,000 IVF cycles per annum in the UAE. Fakih IVF offers a wide range of IVF-related services including intra-cytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), genetic testing, minimal stimulation IVF and male infertility treatments.

The business has one of the highest success rates for IVF services in the country and is the only IVF centre in the Middle East with an in-house Genetics Laboratory performing genetics screening for couples, embryos and also for the advanced personalised medicine. Fakih IVF was also the first to introduce the EmbryoScope in the UAE, a ground-breaking technology in the field of reproductive medicine and was the first centre in the UAE to perform a MicroTESE, a procedure that allows for sperm to be found even if sperm retrievals done earlier did not produce viable sperm for IVF.

Fakih IVF generated a net profit of US$16.6m and had gross assets of US$17.6m and net assets of US$13.7m in the financial year ended 31 March 2014.

Fakih IVF is expected to have a net cash position on its balance sheet at the time of closing.

Website: fakihivf.com

Financing and Financial Impact on NMC

The transaction will be financed using existing cash and credit facilities. NMC expects to retain, post transaction, a net debt to EBITDA level allowing the company financial flexibility for future growth initiatives.

Excluding synergies, the transaction is expected to be significantly accretive to NMC's EPS in 2016 with an attractive ROIC in excess of NMC's cost of capital.

Additional Information on the Transaction

The transaction is subject to customary terms and conditions. NMC expects the transaction to complete by the end of Q1 2016.

Evercore and FGB are acting as Financial Advisors to NMC. In addition, NMC is being advised by Allen & Overy, Clyde & Co. and PwC.

share-week-nmc-great-financial-health

18 Dec Jefferies... 1,350.00 Buy

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 954.53. Over this period, the share price is up 88.08%.

7 Mar Jefferies... 1,350.00 Buy

NMC Royal Hospital Officially Opened
RNS
RNS Number : 3261R
NMC Health Plc
08 March 2016

8 March 2016



NMC ROYAL HOSPITAL, UAE'S LARGEST PRIVATE HEALTHCARE FACILITY OFFICIALLY OPENED



NMC Health plc (LSE:NMC) ('NMC' or the 'Company'), the leading integrated private healthcare provider operating across the United Arab Emirates ('UAE') and one of the top global providers of fertility treatments through its Spanish subsidiary Clinica Eugin, is pleased to announce the official opening of NMC Royal, its newest super speciality hospital, located in the Khalifa area of Abu Dhabi City.



The hospital is now providing inpatient services in addition to outpatient services begun in September 2015.



His Excellency Sheikh Nahayan Mubarak al Nahayan, the Honourable Minister of Culture and Knowledge Development inaugurated the official opening ceremony, which was attended by over 800 dignitaries, medical professionals and media. The delegates were given a tour of the 75,000 square-metre hospital, which has a licensed capacity of 250 beds with the potential to expand to 500 beds within the same premises.



Quartenery care multi specialty hospital



In addition to emergency care and critical care, NMC Royal's comprehensive specialties include neurosciences, cardiac sciences, gastroenterology, hepatology, urology, oncology as well as maternal & child health. A new nephrology unit, in addition to providing dialysis services, will also pioneer the private sector's kidney transplant programs.



NMC Royal's cutting edge technology includes a fully automated laboratory track system that can process up to 25,000 samples a day and over 200 different tests can be done in a single workflow. This computerized robotic system with minimal or no human intervention, significantly reduces turnaround times for doctors and patients and more importantly reduces error rates and risks of cross contamination. NMC Royal Hospital's radiology unit houses a 3 Tesla MRI Unit, whose magnetic field is twice the strength of many standard MRI units, making way for improved imaging and swifter diagnoses - a definitive benefit to neurosurgeons.



NMC's recent acquisition of Europe's leading fertility services provider Eugin and a majority stake in the GCC reproductive services leader Fakih IVF will also provide the latest technological expertise enabling the NMC Royal to set up a full-fledged In Vitro Fertilisation clinic and advanced capabilities for genetic disorders screening.



This capability will also be supported by the integration of wider clinical experience from recent acquisitions such as ProVita's long term acute care and Americare homecare expertise.



NMC Royal services the residents of Khalifa City, Al Raha, Mohammed bin Zayed City, Masdar City, Abu Dhabi International Airport, Shahama and Yas Island suburbs, which according to the Abu Dhabi Economic Vision 2030, are expected to house around one-fifth of the emirate's total population by 2030.



Dr. B.R. Shetty, Executive Vice-Chairman and Chief Executive Officer of NMC Health, commented:



"The opening of our new super speciality hospital, NMC Royal, not only brings long-awaited state-of-the-art medical services, healthcare facilities and emergency care to the residents of Abu Dhabi and the UAE at large, but its medical staff are trained in best global healthcare practices delivering quality healthcare. Central to our hub-and-spoke healthcare platform, NMC Royal will be a regional referral point for best-in-class medical treatment to the growing population of the UAE and NMC's rapidly growing patient population.



"NMC Royal signifies an important step in our strategy. As the largest private healthcare provider in the country with a combined licensed capacity of 885 beds across our integrated healthcare network, we remain uniquely well positioned to leverage our significant clinical expertise, enhanced by recent acquisitions, to deliver sustainable long-term growth and ultimately, shareholder returns."





- ENDS -

Final Results Mon 14 March

Final Results

FY2015 Financial Highlights



· Group reported revenues increased by 36.8% to US$880.9m. Proforma revenues increased by 45.8% to US$938.7m

· Healthcare division revenue increased by 55.7% to US$517.1m1. Proforma healthcare revenues increased by 73.1% to US$575.0m

· Distribution division revenue grew by 16.1% to US$393.4m2

· Reported EBITDA increased by 46.7% to US$150.3m. Proforma EBITDA increased by 61.2% to US$165.2m

· Reported EBITDA margin expanded by 116bps to 17.1%. Proforma EBITDA margins improved by 169bps to 17.6%

· Net profit increased by 10.6% to US$85.8m. Proforma net profit increased by 27.4% to US$98.8m

· Net profit margin declined by 230bps to 9.7% as a result of the accelerated ramp up of new openings leading to higher depreciation as well as the acquisition related amortisations. Proforma net profit margin decreased by 152bps to 10.5%

· Adjusted net profit increased by 21.2% to US$93.9m. Proforma adjusted net profit increased by 42.5% to US$110.5m

· Earnings per share (EPS) amounted to US$0.443 (FY 2014: US$0.412)

· Adjusted earnings per share amounted to US$0.506 (FY 2014: US$0.412)

· Proposed dividend pay-out ratio is maintained at 20% of profit after tax, amounting to GBP3 6.2 pence per share

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 985.00. Over this period, the share price is up 51.38%.

Broker Forecast - Investec issues a broker note on NMC Health PLC

Investec today reaffirms its buy investment rating on NMC Health PLC (LON:NMC) and raised its price target to 1460p (from 1025p). Story provided by StockMarketWire.com

Ex divi 19 May 2016 NMC Health PLC (6.2 P)

Half year report